Skip to main content

Table 2 Correlation between MFN2 expression in tumor tissue with clinicopathological factors in hepatocellular carcinoma patients

From: Clinical significance of mitofusin-2 and its signaling pathways in hepatocellular carcinoma

Variables

MFN2 expression

 

Low

High

P value

n = 58

n = 57

Age (year)

57.1 ± 11.4

57.1 ± 9.9

0.996

Gender (female/male)

3/55

12/45

0.012

HBsAg (no/yes)

15/43

7/50

0.065

HBV-DNA replication (no/yes)

34/24

32/25

0.789

Liver cirrhosis (no/yes)

22/36

18/39

0.476

Preoperative AFP

6292.3 ± 14073.3

4075.1 ± 13793.9

0.048

Tumor number (1/>1)

44/14

42/15

0.789

Tumor size (cm)

6.9 ± 3.6

6.3 ± 3.0

0.610

PV or VI invasion (no/yes)

37/21

43/14

0.177

Lymph node metastasis (no/yes)

51/7

47/10

0.410

Intrahepatic metastasis (no/yes)

38/20

33/24

0.402

Liver capsular invasion (no/yes)

40/18

41/16

0.729

TNM stage (I/II–IV)

23/35

22/35

0.908

Differentiation (well/moderate or poor)

20/38

28/29

0.113

  1. HBsAg hepatitis B surface antigen, HBV-DNA hepatitis B virus deoxyribonucleic acid, AFP alpha-fetoprotein, PV portal vein, VI intrahepatic vein